3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Neoplasm Metastasis
3
Stomatitis
2
Stomach Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Lipoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intracranial Hemorrhages
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Saline Solution
×
Clear all
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled